Biotie bags option to acquire NeurelisPharma Times7 June 2013Neurelis, Biotie Therapies enter option and merger agreementGenetic Engineering & Biotechnology News4 June 2013Biotie puts cocaine dependence drug into Phase IIPharma Times13 May 2013Progress Fighting Parkinson's Drug Side EffectsThe Wall Street Journal25 March 2013Lundbeck gets EU nod for new drug to fight alcohol addictionFierceBiotech28 February 2013UCB licenses global rights to tozadenant in Parkinson's disease from BiotieThe Pharma Letter27 February 2013Treatment for alcoholism 'would save thousands'Pharma Times12 February 2013Biotie considers developing Alzheimer’s drug on its ownBloomberg21 January 2013David Cook appointed chief financial officer of BiotiePharmafile7 January 2013David Cook Named CFO of BiotieCFO Insight2 January 2013CHMP backs Biotie Therapies' Selincro in alcohol dependenceBioWorld15 December 2012Lundbeck's alcohol dependency drug wins EU green lightReuters14 December 2012Lundbeck’s anti-alcoholism pill wins EU regulatory nodBloomberg14 December 2012Biotie rises most in a year on Parkinson’s trial resultsBloomberg11 December 2012Biotie's Parkinson's drug tozadenant clears Phase IIb studyThe Pharma Letter11 December 2012Study: novel therapy limits 'wearing off' periods associated with Parkinson's drugsMichael J Fox Foundation – Foxfeed blog11 December 2012Lundbeck anti-binge drinking drug helps cut intake by 66%Bloomberg5 March 2012Biotie being courted by potential partners for Alzheimer’s drugBloomberg Businessweek20 February 2012Panu Miettinen appointed chief financial officer of BiotieInPharm16 February 2012Lundbeck seeks approval for a novel alcoholism treatmentPharma and Healthcare Insight30 December 2011Biotie tests cocaine dependence treatment in USAPharma Times14 December 2011Scandinavian biotech hit particularly hard in bad year for sectorEPVantage from EvaluatePharma2 December 2011Biotie pulls out of merger with Newron Pharma Times28 October 2011Biotie initiates SYN120 Phase 1 study using PET imagingMedical Devices Business Review25 July 2011Lundbeck to file alcoholism pill this yearInPharm16 June 2011Lundbeck to file alcoholism drug in Europe by year endPharma Times16 June 2011Lundbeck finishes alcohol dependency trialsPMLiVE15 June 2011Lundbeck nails PhIII for drug to curb alcohol dependenceFierceBiotech15 June 2011Nalmefene reaches Phase III endpointsEuropean Biotechnology News6 February 2011Biotie to acquire CNS therapeutics firm Synosia in €93.6M all-shares dealGenetic Engineering & Biotechnology News11 January 2011Biotie buys CNS developer Synosia in $121.5M dealFierceBiotech11 January 2011Alcoholics may stop at one drink with help from Lundbeck anti-abuse drugBloomberg23 December 2010--------------------Päivitetty 10.6.2013